Henlius partners with Sandoz for 10 biosimilar antibodies
Biotechnology company Henlius entered a strategic collaboration with Sandoz on 17 August 2026 covering up to 10 proposed monoclonal antibody biosimilars for global distribution
Shanghai Henlius Biotech, Inc. has reportedly entered into a strategic collaboration with Sandoz, a global leader in generics and biosimilars, to jointly develop up to 10 biosimilar antibodies. According to the partnership agreement, Sandoz will gain exclusive registration and commercialization rights outside China for these products.
The collaboration will also cover the entire product lifecycle, from development to lifecycle management. Henlius will leverage its integrated biologics platform to develop, manufacture, and supply these products. The initial assets covered under the agreement include three proposed biosimilar monoclonal antibodies and one potential recombinant human hyaluronidase.
In return, Sandoz will pay Henlius an upfront payment, milestone payments, and an option fee totaling up to $322 million.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
